Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodal Nonopioid Pain Protocol Following Shoulder Arthroplasty Surgery
NCT05488847Phase 4Active, not recruiting
- Sponsor
- Henry Ford Health
- Start
- Jun 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of oxycodone in shoulder pain and Shoulder arthropathy (2 arms), sponsored by Henry Ford Health. Primary endpoints: Numerical Rating Scale (NRS) Pain Score at 10 days and Morphine Milligram Equivalents at 10 days. Started Jun 2022; status: active, not recruiting.
02
Drugs
oxycodone
03
Conditions
shoulder painShoulder arthropathy
Beyond the preview
Go deeper on NCT05488847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05488847.